
MacroGenics (MGNX) Stock Forecast & Price Target
MacroGenics (MGNX) Analyst Ratings
Bulls say
Macrogenics Inc has demonstrated promising preclinical data for its product candidates, indicating potentially greater potency and improved safety compared to existing therapies, which enhances the attractiveness of its pipeline. The company reported a 3Q24 net income of $0.90 per share, closely aligning with previous forecasts, suggesting stability in financial performance. The overall valuation remains fair, and upcoming datasets could further influence the outlook, potentially positively reinforcing investor confidence in Macrogenics's advancements in cancer therapeutics.
Bears say
Macrogenics Inc. faces a projected full-year net loss of $0.95 per share for 2024, indicating significant financial challenges ahead. The company's primary product, MARGENZA, may struggle to gain market traction due to fierce competition and various market factors, which poses a substantial risk to its financial sustainability. Additionally, potential clinical setbacks with key pipeline candidates, including vobramitamab duocarmazine and lorigerlimab, along with risks related to partnerships and long-term dilution, further contribute to a negative outlook for the company’s stock performance.
This aggregate rating is based on analysts' research of MacroGenics and is not a guaranteed prediction by Public.com or investment advice.
MacroGenics (MGNX) Analyst Forecast & Price Prediction
Start investing in MacroGenics (MGNX)
Order type
Buy in
Order amount
Est. shares
0 shares